Kemp Dolliver
Stock Analyst at Brookline Capital
(0.60)
# 4,127
Out of 5,182 analysts
19
Total ratings
38.46%
Success rate
-17.3%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LSTA Lisata Therapeutics | Downgrades: Hold | n/a | $3.12 | - | 2 | Jan 21, 2026 | |
| RNTX Rein Therapeutics | Downgrades: Hold | n/a | $1.36 | - | 2 | Jan 21, 2026 | |
| VRCA Verrica Pharmaceuticals | Upgrades: Buy | $17 | $6.37 | +166.88% | 3 | Dec 18, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $4.27 | +321.55% | 1 | Jul 21, 2025 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $1.69 | +113.02% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.28 | +1,478.95% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $0.25 | +12,460.00% | 1 | Jan 25, 2024 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $84.62 | +18.18% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $18.28 | +211.90% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $2.67 | +836.33% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $6.57 | +185.39% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.93 | +760.22% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.29 | +1,875.52% | 1 | Feb 2, 2022 |
Lisata Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $3.12
Upside: -
Rein Therapeutics
Jan 21, 2026
Downgrades: Hold
Price Target: n/a
Current: $1.36
Upside: -
Verrica Pharmaceuticals
Dec 18, 2025
Upgrades: Buy
Price Target: $17
Current: $6.37
Upside: +166.88%
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $4.27
Upside: +321.55%
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $1.69
Upside: +113.02%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.28
Upside: +1,478.95%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $0.25
Upside: +12,460.00%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $84.62
Upside: +18.18%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $18.28
Upside: +211.90%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.67
Upside: +836.33%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $6.57
Upside: +185.39%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.93
Upside: +760.22%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.29
Upside: +1,875.52%